射血分数保留的心力衰竭患者中的慢性肾病:内脏脂肪的关键作用
本文综述指出,HFpEF患者中慢性肾病的传统eGFR阈值(<60 mL/min/1.73 m2)未考虑年龄相关生理变化,年龄校正后阈值应为<45 mL/min/1.73 m2,患病率约15%~25%;但心衰及其治疗导致的可逆性肾脏改变使该估计仍偏高。肥胖和内脏脂肪是HFpEF相关慢性肾病的主要驱动因素,减重手术和GLP-1受体激动剂可降低HFpEF和主要肾脏不良结局风险。
要点
- HFpEF患者中慢性肾病患病率约15%~25%(年龄校正eGFR<45 mL/min/1.73 m2),但终末期肾病风险极低(<0.5%/年)。
- 肥胖和内脏脂肪通过神经激素激活和脂肪因子失衡驱动HFpEF及肾小球损伤,是慢性肾病的主要决定因素。
- 减重手术和GLP-1受体激动剂可降低HFpEF和主要肾脏不良结局风险。
核心结论
- 内脏脂肪不仅是HFpEF的主要驱动因素,也是其与慢性肾病关联的主要决定因素。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- HFpEF患者中,年龄校正eGFR<45 mL/min/1.73 m2定义的肾功能受损患病率约15%~25%。
- HFpEF患者终末期肾病风险极低,每年<0.5%,远低于死亡风险。
- 大规模试验中,降血压或降血糖药物努力未对肾小球功能或终末期肾病风险产生有利影响。
- 肥胖和内脏脂肪伴随神经激素激活和脂肪因子分泌失衡,是HFpEF和肾小球损伤及肾小管间质纤维化的既定因果机制。
关键数值与推荐
- HFpEF中固有肾脏病的传统eGFR阈值为<60 mL/min/1.73 m2,年龄校正后阈值为<45 mL/min/1.73 m2。
- 减重手术和GLP-1受体激动剂可降低HFpEF和主要肾脏不良结局风险。
临床怎么用
- 临床评估HFpEF患者肾脏功能时,应考虑年龄校正的eGFR阈值(<45 mL/min/1.73 m2),避免过度诊断慢性肾病。
- 针对肥胖和内脏脂肪的干预(如减重手术、GLP-1受体激动剂)可能降低HFpEF和肾脏不良结局风险。
局限性
- 摘要未明确报告综述的检索范围及纳入研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has been hypothesized that an impairment of kidney function may contribute to the development of heart failure with a preserved ejection fraction (HFpEF). However, the conventional threshold for the identification of intrinsic renal disease in HFpEF (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2) does not consider age-related physiological changes. When adjusted for age, the appropriate threshold is <45 mL/min/1.73 m2, leading to a prevalence of impaired glomerular function of ≈15% to 25% among patients with HFpEF. However, even this estimate of chronic kidney disease is inflated, since heart failure and its treatments lead to reversible changes in renal perfusion, renal venous pressures, and intrarenal hemodynamic changes, which do not reflect structural kidney disease. Accordingly, the risk of end-stage kidney disease in patients with HFpEF is exceptionally low, ie, <0.5% annually, far lower than the risk of death. It is generally assumed that hypertension and diabetes are the most important modifiable risk factors for the development of kidney disease in patients with HFpEF. However, in large-scale trials, pharmacological efforts to lower blood pressure or blood glucose have not had favorable effects on glomerular function or the risk of end-stage kidney disease. Instead, the principal driver of chronic kidney disease in patients with HFpEF appears to be obesity and visceral adiposity. Both obesity and visceral adiposity are accompanied by neurohormonal activation and imbalances in adipokine secretion that are established causal mechanisms-not only of HFpEF-but also of glomerular injury and tubulointerstitial fibrosis-actions that are potentially augmented by increases in the mass of adipose tissue surrounding the kidneys. Alleviation of obesity and visceral adiposity with the use of bariatric surgery and GLP-1 receptor agonists reduces the risk of both HFpEF and major adverse kidney outcomes. The sodium avidity and systemic inflammation seen in patients with HFpEF are not attributable to the presence of intrinsic renal disease, but are likely related to neurohormonal and adipokine-mediated pathways that are driven by secretions from an expanded fat mass. Taken together, these lines of evidence indicate that visceral adiposity is not only the primer driver of HFpEF, but it is also the principal determinant of its association with chronic kidney disease.
引用
- Packer, Testani, Butler, et al. Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity. J Am Coll Cardiol. 2025. PMID: 41091083. doi:10.1016/j.jacc.2025.08.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。